

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stephen H. Leppla et al.

Application No.: 10/088,952

Filed: March 22, 2002

For: MUTATED ANTHRAX TOXIN
PROTECTIVE ANTIGEN PROTEINS
THAT SPECIFICALLY TARGET
CELLS CONTAINING HIGH
AMOUNTS OF CELL-SURFACE
METALLOPROTEINASES OR
PLASMINOGEN ACTIVATOR
RECEPTORS

Examiner: Brandon J. Fetterolf

Technology Center/Art Unit: 1642

Declaration of Stephen Leppla under 37
C.F.R. §1.132

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Stephen H. Leppla, being duly warned that willful false statements and the like are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001, and may jeopardize the validity of the patent application or any patent issuing thereon, state and declare as follows:

1. All statements herein made of my own knowledge are true and statements made on information or belief are believed to be true.

2. I hold a Ph.D. (1969) from the University of Wisconsin, and a Bachelor of Science (1963) from the California Institute of Technology. I am presently Chief, Bacterial Toxins and Therapeutics Section, at the National Institute of Allergy and Infectious Diseases ("NIAID") of the National Institutes of Health ("NIH"). My field of expertise is Bacterial Toxins and Therapeutics. I have authored over one hundred and fifty publications in the field of bacterial toxins, and am a member of the NIAID Working Group on Anthrax Vaccines; the Working Group on Recombinant Toxins, NIH Office of

Biotechnology Activities, OD, NIH; the American Society for Microbiology; and the American Academy of Microbiology. A true copy of my *Curriculum Vitae* is attached hereto as Exhibit A.

3. The present invention is directed to methods of targeting a compound to a cell using a mutant protective antigen. More particularly, the presently claimed invention is directed to methods of targeting a compound to a cell over-expressing a plasminogen activator or a plasminogen activator receptor by administering to the cell (1) a mutant protective antigen protein comprising a urokinase plasminogen activator (uPA)-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by the uPA; and (2) a compound comprising a lethal factor polypeptide comprising a protective antigen binding site; wherein the lethal factor polypeptide binds to cleaved protective antigen and is translocated into the cell, thereby delivering the compound to the cell. The methods can be used to kill tumor cells *in vivo*.

4. I am a named inventor on the above-referenced patent application. I have read and am familiar with the contents of the subject patent application. I have also read the Office Actions received from the United States Patent and Trademark Office dated December 15, 2004 and August 23, 2005. It is my understanding that the Examiner is concerned that the claimed anthrax toxin fusion proteins are obvious over U.S. Patent No. 5,677,274 ("Leppla *et al.*") in view of U.S. Patent No. 5,817,771 ("Bayley *et al.*"). Specifically, the Examiner alleges that Leppla *et al.* discloses all elements of the presently claimed methods except for a mutant protective antigen comprising a plasminogen activator-recognized cleavage site in place of the native furin-recognized cleavage site. The Examiner alleges that Bayley *et al.* disclose that a urokinase plasminogen activator cleavage site can be incorporated into a polypeptide that does not contain such a cleavage site. Based on these disclosures, the Examiner

concludes that the presently claimed methods are obvious in view of the combination of Leppla *et al.* and Bayley *et al.*

5. This declaration is provided to clarify for the Examiner that the presently claimed invention is not obvious in view of the cited references because one of skill in the art would have no reasonable expectation of success in practicing the presently claimed methods based on the combination of Leppla *et al.* and Bayley *et al.* This declaration is further provided to present data demonstrating that the mutant protective antigens of the invention can be used for *in vivo* delivery of a compound to a target cell overexpressing uPA.

6. Leppla *et al.* discloses that a compound can be delivered to a cell using a binary bacterial toxin (*i.e.*, native anthrax protective antigen or an anthrax protective antigen with an HIV-1 protease cleavage site in place of the native protective antigen cleavage site). Leppla *et al.* does not disclose or suggest a mutant protective antigen comprising a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site. Bayley *et al.* does not remedy the deficiency in Leppla *et al.* Bayley *et al.* merely discloses that a uPA cleavage site can be incorporated into a polypeptide (*i.e.*, an alpha hemolysin polypeptide) that does not contain such a cleavage site.

7. Even if one of skill in the art were to combine the disclosures of Leppla *et al.*, and Bayley *et al.* there would be no reasonable expectation of success in being able to practice the presently claimed methods. The present invention is the first demonstration that a mutant protective antigen can be used to deliver a compound to a cell overexpressing a uPA. Binding of a protease to its cleavage site and subsequent proteolytic cleavage is dependent on the three dimensional structure of the proteins. One of skill in the art would not have expected that the uPA overexpressed on the surface of a target cell and the uPA cleavage site on the mutant protective antigen would have come into contact with each other. For example, the uPA cleavage site in the mutant PA might

not be positioned at an appropriate distance from the cell membrane to contact the uPA on the surface of the target cell. Accordingly, there would be no cleavage of the mutant protective antigen by the uPA or delivery of a compound to the target cell.

8. This declaration also presents experiments which demonstrate that the mutant protective antigens of the presently claimed invention are particularly effective for delivering a compound to target cells. Specifically, the experiments demonstrate that the claimed mutant protective antigens can deliver a compound to tumors overexpressing uPA when administered to tumor-bearing mice. These experiments are set forth in Rono *et al.*, *Mol Cancer Ther.* 5(1):89-96 (2006) (copy enclosed as Exhibit B) and unequivocally demonstrate that the mutant protective antigens of the invention can be used for *in vivo* delivery of a compound to a target cell overexpressing uPA. Mutant protective antigens comprising a uPA cleavage site substituted for the native furin cleavage site and compounds comprising a lethal factor polypeptide comprising a protective antigen binding site were systemically administered to mice bearing one of the following types of tumors: B16 melanoma, T241 fibrosarcoma, or Lewis lung carcinoma, all of which overexpress uPA. Administration of the mutant protective antigen and lethal factor polypeptides led to significant tumor growth inhibition, demonstrating that the mutant anthrax protective antigens are cleaved by the uPA expressed by the tumor cells and deliver a compound, *i.e.*, lethal factor, to the cells.

9. In conclusion, it is my scientific opinion that prior to the present invention, one of skill in the art would not have a reasonable expectation of success in practicing the presently claimed methods in view of the teachings of Leppla *et al.* and Bayley *et al.*. The present application provides the first evidence that a mutant protective antigen in which a uPA cleavage site had been substituted for the native furin-recognized cleavage site could be used to deliver a compound to a cell overexpressing uPA. As


Leppia *et al.*
Application No.: 10/088,952
Page 5

Atty. Docket No.: 015280-40510US PATENT

demonstrated by the experiments set forth above, the mutant protective antigens of the invention are particularly effective for *in vivo* delivery of a compound to a target cell.

Dated: 22 Feb 2006

By: _____



Stephen H. Leppia, Ph.D.

60504268

CURRICULUM VITAE

Stephen H. Leppla, Ph.D.

EDUCATION

- 1959-63 B.S. Biology, California Institute of Technology
- 1963-69 Ph.D. Biochemistry, Biochemistry Department
University of Wisconsin, Madison
Characterization of yeast ribonucleic acids

EMPLOYMENT HISTORY

- 1969-71 National Institutes of Health Postdoctoral Fellow
Dept. of Molecular Biology, University of California, Berkeley, CA.
Studies of the control of RNA synthesis in bacteria, using chemical
and genetic techniques. Terminal nucleotide analysis of viral RNAs.
- 1971-73 Research Associate, Division of Biological and Medical Sciences,
Brown University, Providence, RI.
Biochemistry of schistosomiasis.
Isolation of enzymatically and serologically-active materials.
- 1974-89 Research Chemist (and Division Chief during 1983-1985)
Bacteriology Division,
U.S. Army Medical Research Institute of Infectious Diseases,
Frederick, MD.
Characterization of bacterial toxins.
- 1989-2001 Research Chemist, Oral Infection and Immunity Branch
National Institute of Dental and Craniofacial Research
National Institutes of Health, Bethesda, MD.
Structure and function of bacterial protein toxins.
- 2001-present Senior Investigator
Chief, Bacterial Toxins and Therapeutics Section
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Bethesda, MD.
Structure and function of bacterial protein toxins.

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

- 1974-present American Society for Microbiology
- 1985-present American Academy of Microbiology

OTHER ACTIVITIES

1980-1987	Member, Editorial Board, Infection and Immunity
1987-1991	Editor, Infection and Immunity
1995-1998	Member, NIH Institutional Biosafety Committee
1998-	Member, NIAID Working Group on Anthrax Vaccines
2000-	Member, Working Group on Recombinant Toxins, NIH Office of Biotechnology Activities, OD, NIH

Publications:

1. **Leppla, S. H.**, B. Bjoraker, and R. M. Bock.
Borohydride reduction of periodate-oxidized chain ends (RNA).
Methods in Enzymology 12:236, Academic Press. 1968.
2. Lewandowski, L. J., J. Content, and **S. H. Leppla**.
Characterization of the subunit structure of the ribonucleic acid genome of influenza virus.
J. of Virology 8:701-707. 1971.
3. Lewandowski, L. J. and **S. H. Leppla**.
Comparison of the 3' termini of discrete segments of the double-stranded ribonucleic acid genomes of cytoplasmic polyhedrosis virus, wound tumor virus, and reovirus.
J. of Virology 10:965-968. 1972.
4. **Leppla, S. H.**
Large-scale purification and characterization of the exotoxin of *Pseudomonas aeruginosa*.
Infect. Immun. 14:1077-1086. 1976.
5. White, J. D., J. V. Jemski, G. H. Scott, R. A. Kishimoto and **S. H. Leppla**.
Scanning electron microscopy of experimentally induced respiratory infections.
Scanning Electron Microscopy/1977, Vol. II. 1977.
6. **Leppla, S. H.**, O. C. Martin, and L. A. Muehl.
The exotoxin of *P. aeruginosa*: A proenzyme having an unusual mode of activation.
Biochem. Biophys. Res. Commun. 81:532-538. 1978.
7. Snell, K., I. A. Holder, **S. H. Leppla**, and C. B. Saelinger.
Role of exotoxin and protease as possible virulence factors in experimental infections with *Pseudomonas aeruginosa*.
Infect. Immun. 19:839-845. 1978.
8. Middlebrook, J. L., R. B. Dorland, and **S. H. Leppla**.
Association of diphtheria toxin with Vero cells: Evidence for a receptor.
J. Biol. Chem. 253:7325-7330. 1978.
9. Middlebrook, J. L., R. B. Dorland, and **S. H. Leppla**.
Effects of lectins on the interaction of diphtheria toxin with mammalian cells.
Exp. Cell Res. 121:95-101. 1979.
10. Walker, H. L., C. G. McLeod, Jr., **S. H. Leppla**, and A. D. Mason, Jr.
Evaluation of *Pseudomonas aeruginosa* toxin A in experimental rat burn wound sepsis.
Infect. Immun. 25:828-830. 1979.
11. Dorland, R. B., J. L. Middlebrook, and **S. H. Leppla**.
Receptor-mediated internalization and degradation of diphtheria toxin by monkey kidney cells.
J. Biol. Chem. 254:11337-11342. 1979.
12. **Leppla, S. H.**, R. B. Dorland, and J. L. Middlebrook.
Inhibition of diphtheria toxin degradation and cytotoxic action by chloroquine.

J. Biol. Chem. 255:2247-2250. 1980.

13. Brown, J. E., M. A. Ussery, **S. H. Leppla**, and S. W. Rothman.
Inhibition of protein synthesis by shiga toxin.
FEBS Letters 117:84-88. 1980.

14. Middlebrook, J. L., R. B. Dorland, **S. H. Leppla**, and J. D. White.
Receptor-mediated binding and internalization of *Pseudomonas* exotoxin A and diphtheria exotoxin by mammalian cells.
In "Natural Toxins", International Symposium on Animal, Plant, and Microbial Toxins, pp. 463-470, D. Eaker and T. Wadstrom, eds., Pergamon Press. 1980.

15. **Leppla, S. H.** and R. B. Dorland.
Uptake mechanisms for ADP-ribosylating toxins.
In "Receptor-Mediated Binding and Internalization of Toxins and Hormones", pp. 65-79, J. L. Middlebrook and L. Kohn, eds., Academic Press. 1981.

16. Pavlovskis, O. R., D. C. Edman, **S. H. Leppla**, B. Wretling, L. R. Lewis, and K. E. Martin.
Protection against experimental *Pseudomonas aeruginosa* infection in mice by active immunization with exotoxin A toxoids.
Infect. Immun. 32:681-689. 1981.

17. Dorland, R. B., J. L. Middlebrook, and **S. H. Leppla**.
Effect of ammonium chloride on receptor-mediated uptake of diphtheria toxin by Vero cells.
Exp. Cell Res. 134:319-327. 1981.

18. **Leppla, S. H.**
Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells.
Proc. Natl. Acad. Sci. USA 79:3162-3166. 1982.

19. Vodkin, M. H. and **S. H. Leppla**.
Cloning of the protective antigen gene of *Bacillus anthracis*.
Cell 34:693-697. 1983.

20. Mikesell, P., B. E. Ivins, J. D. Ristroph, M. H. Vodkin, T. M. Drier, and **S. H. Leppla**.
Plasmids, Pasteur, and Anthrax.
ASM News, pp. 320-322. Amer.Soc. Microb. 1983.

21. **Leppla, S. H.**
Bacillus anthracis calmodulin dependent adenylate cyclase: chemical and enzymatic properties and interactions with eukaryotic cells.
In Adv. Cyclic Nucleotide and Protein Phosphor. Res. 17:189-198.
Raven Press, New York. 1984.

22. Manhart, M. D., R. E. Morris, P. F. Bonventre, **S. Leppla**, and C. B. Saelinger.
Evidence for *Pseudomonas* exotoxin A receptors on plasma membrane of toxin-sensitive LM fibroblasts.
Infect. Immun. 45:596-603. 1984.

23. Ezzell, J. W., B. E. Ivins, and **S. H. Leppla**.
Immunoelectrophoretic analysis, toxicity, and kinetics of *in vitro* production of the protective antigen and lethal factor components of *Bacillus anthracis* toxin.
Infect. Immun. 45:761-767. 1984.

24. O'Brien, J., A. Friedlander, T. Drier, J. Ezzell, and **S. Leppla**.
The effects of anthrax toxin components on human neutrophils.
Infect. Immun. 47:306-310. 1985.

25. Allured, V. S., L. M. Case, **S. H. Leppla**, and D. B. McKay.
Crystallization of the protective antigen protein of *Bacillus anthracis*.
J. Biol. Chem. 260:5012-5013. 1985.
26. Wade, B. H., G. G. Wright, E. L. Hewlett, **S. H. Leppla**, and G. L. Mandell.
Anthrax toxin components stimulate chemotaxis of human polymorphonuclear neutrophils.
Proc. Soc. Expt. Biol. Med. 179:159-162. 1985.
27. **Leppla, S. H.**, B. E. Ivins, and J. W. Ezzell, Jr.
Anthrax toxin.
In "Microbiology --1985", L. Leive, ed. American Society for Microbiology, Washington, D.C., p 63-66. 1985.
28. Ezzell, J. W., P. Mikesell, B. E. Ivins, and **S. H. Leppla**.
The genetic basis of Pasteur's attenuation of *Bacillus anthracis* cultures
In "World's Debt to Pasteur", H. Koprowski and S. A. Plotkin, eds., Alan R. Liss, Inc., New York, N.Y. 1985.
29. Ivins, B. E., J. W. Ezzell, Jr., K. W. Hedlund, J. D. Ristroph, and **S. H. Leppla**.
Immunization studies with attenuated strains of *Bacillus anthracis*.
Infect. Immun. 52:454-458. 1986.
30. **Leppla, S. H.**, D. L. Robertson, S. L. Welkos, L. A. Smith, and M. H. Vodkin.
Cloning and analysis of genes for anthrax toxin components.
In Proceeding of the Second European Workshop on Bacterial Protein Toxins, P. Falmagne et al (Eds.). Zentralblatt
fur Bakteriologie, Mikrobiologie, und Hygiene I. Abteilung. Gustav Fischer, Stuttgart and New York, 1986.
31. Robertson, D. L. and **S. H. Leppla**.
Molecular cloning and expression in *Escherichia coli* of the lethal factor gene of *Bacillus anthracis*.
Gene 44:71-78. 1986.
32. Larson, D. K., G. J. Calton, J. W. Burnett, S. F. Little, and **S. H. Leppla**.
Purification of *Bacillus anthracis* protective antigen by immunosorbent chromatography.
Enzyme Microb. Technol. 10:14-18. 1988.
33. Gordon, V. M., **S. H. Leppla**, and E. L. Hewlett.
Inhibitors of receptor-mediated endocytosis block the entry of *Bacillus anthracis* adenylate cyclase toxin,
but not *Bordetella pertussis* adenylate cyclase toxin.
Infect. Immun. 56:1066-1069. 1988.
34. **Leppla, S. H.**
Production and purification of anthrax toxin.
In "Methods in Enzymology", S. Harshmann, ed. Academic Press, New York, N.Y., Vol 165, p. 103-116. 1988.
35. Little, S. F., **S. H. Leppla**, and E. M. Cora.
Production and characterization of monoclonal antibodies against the protective antigen component of
Bacillus anthracis toxin.
Infect. Immun. 56:1807-1813. 1988.
36. Welkos, S. L., J. R. Lowe, F. Eden-McCutchan, M. Vodkin, **S. H. Leppla**,
and J. J. Schmidt.
Sequence and Analysis of the DNA encoding protective antigen of *Bacillus anthracis*.
Gene 69:287-300. 1988.
37. Turnbull, P. C. B., **S. H. Leppla**, M. G. Broster, C. P. Quinn, and J. Melling.
Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
Med. Microbiol. Immun. 177:293-303. 1988.
38. **Leppla, S. H.**, A. M. Friedlander, and E. M. Cora.
Proteolytic activation of anthrax toxin bound to cellular receptors
In "Bacterial Protein Toxins", F. J. Fehrenbach, J. E. Alouf, P. Falmagne, W. Goebel, J. Jeljaszewicz, D. Jurgen, and
R. Rappuoli, (eds.), p. 111-112. Gustav Fischer Verlag, Stuttgart, New York. 1988.

39. Robertson, D. L., M. T. Tippetts, and S. H. Leppla.
Nucleotide sequence of the *Bacillus anthracis* edema factor gene (cya):
A calmodulin-dependent adenylate cyclase.
Gene 73:363-371. 1988.
40. Larson, D. K., G. J. Calton, S. F. Little, S. H. Leppla and J. W. Burnett.
Separation of three exotoxins of *Bacillus anthracis* by sequential immunosorbent chromatography.
Toxicon 26:913-921. 1988.
41. Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander.
Internalization and processing of *Bacillus anthracis* lethal toxin by toxin-sensitive and -resistant cells.
J. Biol. Chem. 264:11099-11102. 1989.
42. Bhatnagar, R., Y. Singh, S. H. Leppla, and A. M. Friedlander.
Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1.
Infect. Immun. 57:2107-2114. 1989.
43. Bartkus, J. M. and S. H. Leppla.
Transcriptional regulation of the protective antigen gene of *Bacillus anthracis*.
Infect. Immun. 57:2295-2300. 1989.
44. Gordon, V. M., W. W. Young, Jr., S. M. Lechler, S. H. Leppla, and E. L. Hewlett.
Adenylate cyclase toxins from *Bacillus anthracis* and *Bordetella pertussis*:
Different processes for interaction with and entry into target cells.
J. Biol. Chem. 264:14792-14796. 1989.
45. Singh, Y., V. K. Chaudhary, and S. H. Leppla.
A deleted variant of *Bacillus anthracis* protective antigen is non-toxic and blocks anthrax toxin action in vivo.
J. Biol. Chem. 264:19103-19107. 1989.
46. Leppla, S. H., A. M. Friedlander, Y. Singh, E. M. Cora, and R. Bhatnagar.
A model for anthrax toxin action at the cellular level.
Salisbury Med. Bull., No. 68, Special Supplement, p. 41-43. 1990.
47. Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander.
Basis of cellular sensitivity and resistance to anthrax lethal toxin.
Salisbury Med. Bull., No. 68, Special Supplement, p. 46-48. 1990.
48. Bartkus, J. M. and S. H. Leppla.
Use of gene fusions to study expression of virulence genes in *Bacillus anthracis*.
Salisbury Med. Bull., No. 68, Special Supplement, p. 67-69. 1990.
49. Little, S. F., S. H. Leppla and A. M. Friedlander.
Production and characterization of monoclonal antibodies against the lethal factor component of *Bacillus anthracis* lethal toxin.
Infect. Immun. 58:1606-1613. 1990.
50. Leppla, S. H.
Purification and characterization of adenylate cyclase from *Bacillus anthracis*.
In "Methods in Enzymology", R. A. Johnson and J. D. Corbin, eds. Academic Press, New York, N.Y., Vol 195,
p. 153-168. 1991.
51. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla.
The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.
J. Biol. Chem. 266:15493-15497. 1991.
52. Quinn, C. P., K. R. Klimpel, Y. Singh, and S. H. Leppla.
Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis.
J. Biol. Chem. 266:20124-20130. 1991.

53. **Leppla, S. H.**

The anthrax toxin complex.

in Sourcebook of Bacterial Protein Toxins, pp. 277-302, J. A. Alouf and J. Freer, eds, Academic Press. 1991.

54. Klimpel, K. R., **S. H. Leppla**, Y. Singh and C. P. Quinn.

Fine structure analysis of the amino acid sequence recognized by the eukaryotic cell protease that activates anthrax toxin.

In "Bacterial Protein Toxins", B. Witholt, J. E. Alouf, G. J. Boulnois, P. Cossart, B. W. Dijkstra, P. Falmagne, F. J. Fehrenbach, J. Freer, H. Niemann, R. Rappuoli, and T. Wadstrom (eds.), p. 490-491. Gustav Fischer Verlag, Stuttgart, New York. 1992.

55. Arora, N., K. R. Klimpel, Y. Singh, and **S. H. Leppla**.

Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of *Pseudomonas exotoxin A* are potent cytotoxins which are translocated to the cytosol of mammalian cells.

J. Biol. Chem. 267:15542-15548. 1992.

56. Molloy, S. S., P. A. Bresnahan, **S. H. Leppla**, K. R. Klimpel, and G. Thomas.

Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen.

J. Biol. Chem. 267:16396-16402. 1992.

57. Novak, J. M., M.-P. Stein, S. F. Little, **S. H. Leppla**, and A. M. Friedlander.

Functional characterization of protease-treated *Bacillus anthracis* protective antigen.

J. Biol. Chem. 267:17186-17193. 1992.

58. Klimpel, K. R., S. S. Molloy, G. Thomas, and **S. H. Leppla**.

Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

Proc. Natl. Acad. Sci. USA, 89:10277-10281. 1992.

59. Friedlander, A. M., R. Bhatnagar, **S. H. Leppla**, L. Johnson, and Y. Singh.

Characterization of macrophage sensitivity and resistance to anthrax lethal toxin.

Infect. Immun. 61:245-252. 1993.

60. Arora, N. and **S. H. Leppla**.

Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides.

J. Biol. Chem. 268:3334-3341. 1993.

61. Uchida, I., J. M. Hornung, C. B. Thorne, K. R. Klimpel, and **S. H. Leppla**.

Cloning and characterization of a gene whose product is a *trans*-activator of anthrax toxin synthesis.

J. Bacteriol. 175:5329-5338. 1993.

62. Gordon, V. M. and **S. H. Leppla**.

Proteolytic activation of bacterial toxins. Role of bacterial and host cell proteases. (Minireview)

Infect. Immun. 62:333-340. 1994.

63. Little, S. F., **S. H. Leppla**, J. W. Burnett, and A. M. Friedlander.

Structure-function analysis of *Bacillus anthracis* edema factor by using monoclonal antibodies.

Biochem. Biophys. Res. Comm., 199:676-682. 1994.

64. **Leppla, S. H.**, Kurt R. Klimpel, and N. Arora.

Development of anthrax toxin-based fusion proteins for targeting of HIV-1-infected cells.

In "Bacterial Protein Toxins", Zbl. Bakt. Suppl.24, J. Freer, F. J. Fehrenbach, and others (eds.), Gustav Fischer, Stuttgart, Jena, New York pp. 431-442.

65. Klimpel, K. R., N. Arora, **S. H. Leppla**.

Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity.

Mol. Microbiol., 13:1093-1100. 1994.

66. Arora, N. and **S. H. Leppla**.
Fusions of anthrax toxin lethal factor with Shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
Infect. Immun., 62:4955-4961. 1994.
67. FitzGerald, D.J., C.M. Fryling, A. Zdanovsky, C.B. Saelinger, M. Kounnas, D.K. Strickland, and **S. Leppla**.
Selection of *Pseudomonas* exotoxin-resistant cells with altered expression of α_2 MR/LRP.
Ann. N. Y. Acad. Sci. 737:138-144. 1994.
68. Arora, N., L. C. Williamson, **S. H. Leppla**, and J. L. Halpern.
Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells.
J. Biol. Chem. 269:26165-26171. 1994.
69. Singh, Y., K. R. Klimpel, N. Arora, M. Sharma, and **S. H. Leppla**.
The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.
J. Biol. Chem., 269:29039-29046. 1994.
70. Friedman, T. C., V. M. Gordon, **S. H. Leppla**, K. R. Klimpel, N. P. Birch, and Y. P. Loh.
In vitro processing of anthrax toxin protective antigen by recombinant PC1(SPC3) and bovine intermediate lobe secretory vesicle membranes.
Arch. Biochem. Biophys., 316:5-13. 1995.
71. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and **S. H. Leppla**.
The proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases.
Infect. Immun. 63:82-87. 1995.
72. **Leppla, S. H.**, K. R. Klimpel, and N. Arora.
Anthrax toxin mechanisms of receptor binding and internalization. pp. 127-139,
in Molecular Mechanisms of Bacterial Virulence, C. I. Kado and J. H. Crosa, eds.,
Kluwer Academic Publishers, Hingham, MA, 1994.
73. **Leppla, S. H.**
Anthrax toxins. pp. 543-572.
In Bacterial Toxins and Virulence Factors in Disease. Volume 8 of the Handbook of Natural Toxins.
Moss, J., B. Iglewski, M. Vaughan, and A. T. Tu, eds.
Marcel Dekker, 1995.
74. FitzGerald, D.J., C. M. Fryling, A. Zdanovsky, C. B. Saelinger, M. Kounnas, J. A. Winkles, D. Strickland, and **S. Leppla**.
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low density lipoprotein-related protein.
J. Cell Biol. 129:1533-1541 1995.
75. Gu, M.-L., J. Rappaport, and **S. H. Leppla**.
Furin is important but not essential to the processing of HIV-1 gp160.
FEBS Lett. 365:95-97. 1995.
76. Gu, M., V. M. Gordon, D. J. P. FitzGerald, and **S. H. Leppla**.
Furin regulates both the activation of *Pseudomonas* exotoxin A and the quantity of the toxin receptor expressed on target cells.
Infect. Immun. 64:524-527. 1996.
77. Little, S. F., J. M. Novak, J. R. Lowe, **S. H. Leppla**, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander.
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of *Bacillus anthracis* using monoclonal antibodies.

78. Petosa, C., R. J. Collier, K. R. Klimpel, **S. H. Leppla**, and R. C. Liddington.
Crystal structure of the anthrax toxin protective antigen.
Nature 385:833-838. 1997
79. Gordon, V. M., A. Rehemtulla, and **S. H. Leppla**.
A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen.
Infect. Immun. 65:3370-3375. 1997.
80. Goletz, T. J., K. R. Klimpel, **S. H. Leppla**, J. M. Keith, and J. A. Berzofsky.
Delivery of antigens to the MHC Class I pathway using bacterial antigens.
Hum. Immun. 54:129-136. 1997.
81. **Leppla, S.H.**
Anthrax edema factor (*Bacillus anthracis*), p. 41-43.
in Guidebook to Protein Toxins and their Use in Cell Biology, R. Rappuoli and C. Montecucco, eds.,
Oxford University Press, 1997.
82. Gordon, V. M., R. Benz, K. E. Fujii, **S. H. Leppla**, and R. K. Tweten.
Clostridium septicum alpha toxin is proteolytically activated by furin.
Infect. Immun. 65:4130-4134. 1997.
83. Goletz, T. J., K. R. Klimpel, N. Arora, **S. H. Leppla**, J. M. Keith, and J. A. Berzofsky.
Targeting HIV proteins to the MHC Class I processing pathway with a novel gp-120-anthrax toxin fusion protein.
Proc. Natl. Acad. Sci. 94:12059-12064. 1997.
84. Varughese, M., A. Chi, A. V. Teixeira, P. J. Nicholls, J. M. Keith, and **S. H. Leppla**.
Internalization of a *Bacillus anthracis* protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies.
Mol. Med. 4:87-95. 1998.
85. Duesbery, N. S., C. P. Webb, **S. H. Leppla**, V. M. Gordon, K. R. Klimpel, T. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, and G. F. Vande Woude.
Proteolytic inactivation of MAP-Kinase-Kinase by anthrax lethal factor.
Science. 280:734-737. 1998.
86. Singh, Y., B. E. Ivins, and **S. H. Leppla**.
Study of immunization against anthrax with the purified recombinant protective antigen of *Bacillus anthracis*.
Infect. Immun. 66:3447-3448. 1998.
87. Leppla, S. H.
Anthrax toxin lethal factor, p. 1491-1492.
in: Handbook of Proteolytic Enzymes, A.J. Barrett, N. D. Rawlings, and J. F. Woessner, eds.,
Academic Press, 1998.
88. Abrami, L., M. Fivaz, E. Decroly, N. G. Seidah, F. Jean, G. Thomas, **S. H. Leppla**, J. T. Buckley, and F. G. van der Goot
The pore-forming toxin proaerolysin is activated by furin.
J. Biol. Chem. 273:32656-32661. 1998.
89. Gu, M.L., **S. H. Leppla**, and D. M. Klinman
Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen.
Vaccine, 17:340-344. 1999.
90. Singh, Y., K. R. Klimpel, S. Goel, P. K. Swaim, and **S. H. Leppla**.
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.
Infect. Immun. 67:1853-1859. 1999.

91. Varughese, M., A. V. Teixeira, S. Liu, and **S. H. Leppla**.
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.
Infect. Immun. 67:1860-1865. 1999.
92. Tang, G. and **S. H. Leppla**.
Proteasome activity is required for anthrax lethal toxin to kill macrophages
Infect. Immun. 67:3055-3060. 1999.
93. **Leppla, S. H.**
The bifactorial *Bacillus anthracis* lethal and oedema toxins. P. 243-263
in *Comprehensive Sourcebook of Bacterial Protein Toxins*, 2nd edition, J. A. Alouf and J. Freer, eds, Academic Press, London, in press, 1999.
94. Gordon, V. M., K. L. Nelson, J. T. Buckley, V. L. Stevens, R. K. Tweten, and **S. H. Leppla**.
Clostridium septicum alpha toxin uses glycosylphosphatidylinositol-anchored protein receptor
J. Biol. Chem. 274:27274-27280. 1999.
95. Park, S. and **S. H. Leppla**.
Optimized production and purification of *Bacillus anthracis* lethal factor.
Prot. Express. Purif. 18:293-302. 2000.
96. **Leppla, S. H.**
Anthrax toxin.
in: *Bacterial Protein Toxins, Handbook of Experimental Pharmacology*, Vol 145 : Eds. K. Aktories & I. Just
Springer-Verlag GmbH & Co. KG; Berlin. Pp 445-472. 2000.
97. Liu, S., S. Netzel-Arnett, H. Birkedal-Hansen, and **S. H. Leppla**
Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin
Cancer Res. 60:6061-6067. 2000.
98. Duesbery, N. S., J. Resau, C. P. Webb, S. Koochekpour, H.-M. Koo, **S. H. Leppla**, and G. F. Vande Woude
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways
Proc. Natl. Acad. Sci. 98:4089-4094. 2001.
99. Liu, S., T. H. Bugge, and **S. H. Leppla**
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
J. Biol. Chem. 276:17976-17984. 2001.
100. **Leppla, S. H.**
A dominant-negative therapy for anthrax. (News & Views commentary)
Nature Med. 7:659-660. 2001.
101. Price, B. M., A. L. Liner, S. Park, **S. H. Leppla**, A. Mateczun, and D. R. Galloway.
Protection against lethal anthrax toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
Infect Immun. 69:4509-4515. 2001.
102. Moriya, O, M. Matsui, M. Osorio, H. Miyazawa, C. M. Rice, S. M. Feinstone, **S. H. Leppla**, J. M. Keith, and T. Akatsuka. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein.
Vaccine, 2942:1-8. 2001.
103. Pannifer, A., T. Y. Wong, R. Schwarzenbacher, M. Renatus, C. Petosa, J. Bienkowska, D. B. Lacy, R. J. Collier, S. Park, **S. H. Leppla**, P. Hanna, and R. C. Liddington.
Crystal Structure of the Anthrax Lethal Factor.
Nature, 414:229-233. 2001.
104. Chaudry, G. J., M. Moayeri, S. Liu and **S. H. Leppla**.
Quickening the pace of anthrax research: three advances point toward possible therapies

Trends in Microbiology, 10:58-62. 2002.

105. Koo, H. M., M. VanBrocklin, M. J. McWilliams, **S. H. Leppla**, N. S. Duesbery, and G. F. Vande Woude. Apoptosis and melanogenesis in human melanoma cells induced by anthrax toxin lethal factor inactivation of mitogen-activated protein kinase kinase
Proc. Natl. Acad. Sci. 99:3052-3057. 2002.

106. Frankel, A. E., T. H. Bugge, S. Liu, D. A. Vallera, and **S. H. Leppla**. Peptide toxins directed at the matrix dissolution systems of cancer cells.
Prot. Pept. Letters 9:1-14. 2002.

107. Ramirez, D., **S. H. Leppla**, R. Schneerson, and J. Shiloach. Production, recovery and immunogenicity of the protective antigen from a recombinant strain of *Bacillus anthracis*
J. Indus. Micro. & Biotech. 28:232-238. 2002.

108. Maynard, J. A., C. B. M. Maassen, **S. H. Leppla**, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity
Nature Biotech. 20:597-601. 2002.

109. **Leppla, S. H.**, J. B. Robbins, R. Schneerson, and J. Shiloach. Development of an improved vaccine for anthrax
J. Clin. Invest. 110:141-144. 2002.

110. Frankel, A. E., B. L. Powell, N. S. Duesbery, G. F. Vande Woude, and **S. H. Leppla**. Anthrax fusion protein therapy of cancer
Curr. Prot. & Pept. Ther. of Cancer. 3:399-407. 2002.

111. Rosovitz, M. J. and **S. H. Leppla**. Medicine: Virus deals anthrax a killer blow (News & Views)
Nature. 418:825-826. 2002.

112. Liu, S. and **S. H. Leppla**. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization
J. Biol. Chem. 278:5227-5234 2003.

113. Abrami, L., S. Liu, P. Cosson, **S. H. Leppla**, and F. G. van der Goot. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 160:321-328. 2003.

114. Liu, S., H. Aaronson, D. J. Mitola, **S. H. Leppla**, and T. H. Bugge. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Proc. Natl. Acad. Sci. U. S. A 100:657-662. 2003.

115. Webster, J. I., L. H. Tonelli, M. Moayeri, S. S. Simons, Jr., **S. H. Leppla**, and E. M. Sternberg. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity.
Proc. Natl. Acad. Sci. U. S. A. 100:5706-5711. 2003.

116. Rosovitz, M. J., P. Schuck, M. Varughese, A. P. Chopra, V. Mehra, Y. Singh, L. M. McGinnis, and **S. H. Leppla**. Alanine scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.
J. Biol. Chem. 278:30936-30944. 2003.

117. Boyaka, P. N., A. Tafaro, R. Fischer, **S. H. Leppla**, K. Fujihashi, and J. R. McGhee. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
J. Immunol. 170:5636-5643. 2003.

118. Agrawal, A., J. Lingappa, **S. H. Leppla**, S. Agrawal, A. Jabbar, C. Quinn and B. Pulendran. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin

Nature 424:329-334. 2003.

119. Schneerson, R., J. Kubler-Kielb, T. Y. Liu, Z. D. Dai, A. Yergey, P. Backlund, J. Shiloach, **S. H. Leppla**, F. Majadly, and J. B. Robbins.
Poly(γ -D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of *Bacillus anthracis*: A potential addition to the anthrax vaccine
Proc. Natl. Acad. Sci. USA 100:8945-8950. 2003.

120. Liu, S., R. L. Schubert, T. H. Bugge, and **S. H. Leppla**.
Anthrax toxin: structures, functions, and tumor targeting.
Expert Opin. Biol. Ther. 3(5):843-855. 2003.

121. Moayeri, M., D. Haines, H. A. Young, and **S. H. Leppla**.
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.
J. Clin. Inv. 112:670-682. 2003.

122. Frankel, A. E., D. M. Neville, T. A. Bugge, R. J. Kreitman, and **S. H. Leppla**.
Immunotoxin therapy of hematologic malignancies.
Semin. Oncol. 30:545-557. 2003.

123. Liu, S. and **S. H. Leppla**.
Retroviral insertional mutagenesis identifies a small protein required for synthesis of diphthamide, the target of bacterial ADP-ribosylating toxins.
Mol. Cell 12:603-613. 2003.

124. Frankel, A. E., H. M. Koo, **S. H. Leppla**, N. S. Duesbery, and G. F. Vande Woude.
Novel protein targeted therapy of metastatic melanoma.
Curr. Pharm. Design 9:2060-2066. 2003.

125. Pomerantsev, A. P., K. V. Kalnin, M. Osorio, and **S. H. Leppla**.
Phosphatidylcholine-specific phospholipase C and sphingomyelinase activities in bacteria of the *Bacillus cereus* Group.
Infect. Immun. 71:6591-6606. 2003.

126. Turk, B. E., T. Y. Wong, R. Schwarzenbacher, E. T. Jarrell, **S. H. Leppla**, R. J. Collier, R. C. Liddington, and L. C. Cantley.
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor.
Nature Struc. Mol. Biol. 11:60-66. 2004.

127. Sarac, M. S., J. R. Peinado, **S. H. Leppla**, and I. Lindberg.
Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.
Infect. Immun. 72(1):602-605. 2004.

128. Cui, X., M. Moayeri, Y. Li, X. Li, M. Haley, Y. Fitz, R. Correa-Araujo, S. M. Banks, **S. H. Leppla**, and P. Q. Eichacker.
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.
Am. J. Physiol Regul. Integr. Comp. Physiol. 286(4):R699-R709. 2004.

129. Moayeri, M. and **S. H. Leppla**. The roles of anthrax toxin in pathogenesis.
Curr. Op. Microb. 7:19-24. 2004.

130. Abi-Habib, R. J., S. Liu, T. A. Bugge, **S. H. Leppla** and A. E. Frankel.
A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor (DTU2GMCSF) is selectively cytotoxic to human acute myeloid leukemia blasts.
Blood Published online, 25 May.

131. Santelli, E., L. A. Bankston, **S. H. Leppla**, and R. C. Liddington.
Crystal structure of a complex between an anthrax toxin and its host cell receptor
Nature 430:905-908. 2004.

132. Moayeri, M., N. Martinez, H. A. Young, and **S. H. Leppla**.
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors additional to those controlling macrophage sensitivity.
Infect. Immun., 72:4439-4447. 2004.
133. Abrami, L., M. Lindsay, R. G. Parton, **S. H. Leppla**, and F. G. van der Goot.
Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway.
J. Cell Biol. 166:645-651. 2004.
134. Peinado, J. R., M. M. Kacprzak, **S. H. Leppla**, and I. Lindberg.
Cross-inhibition between furin and LF inhibitors.
Biochem. Biophys. Res. Commun. 321:601-605. 2004.
135. Pomerantsev, A. P., O. M. Pomerantseva, and **S. H. Leppla**.
A spontaneous translational fusion of *Bacillus cereus* PlcR and PapR activates transcription of PlcR-Dependent genes in *Bacillus anthracis* via binding with a specific palindromic sequence.
Infect. Immun. 72:5814-5823. 2004.
136. Liu, S., G. T. Milne, J. G. Kuremsky, G. R. Fink, and **S. H. Leppla**.
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP_ribosylating toxins on elongation factor 2.
Mol. Cell Biol. 24:9487-9497. 2004.
137. Watson, J. V. Koya, **S. H. Leppla**, and H. Daniell.
Expression of *Bacillus anthracis* protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop.
Vaccine 22:4374-4384. 2004.
138. Ren, G., J. Quispe, **S. H. Leppla**, and A. K. Mitra.
Large-scale structural changes accompany binding of lethal factor to anthrax protective antigen: A cryo-electron microscopic study.
Structure (Camb.) 12:2059-2066. 2004.
139. Westcott, M. M., R. J. Abi-Habib, K. A. Cohen, M. C. Willingham, S. Liu, T. H. Bugge, **S. H. Leppla** and A. E. Frankel.
Diphtheria toxin-murine GM-CSF-induced hepatotoxicity is mediated by Kupffer cells.
Mol. Cancer Ther. 3:1681-1689. 2004.
140. Cui, X., Y. Li, M. Moayeri, G. H. Choi, G. M. Subramanian, X. Li, M. Haley, Y. Fitz, J. Feng, S. M. Banks, **S. H. Leppla**, and P. Q. Eichacker.
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis
J. Inf. Dis. 191:422-434. 2005
141. Liu, S., V. Redeye, J. G. Kuremsky, M. Kuhnen, A. Molinolo, T. H. Bugge, and **S. H. Leppla**
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin
Nature Biotech 23:725-730. 2005.
142. Moayeri, M., J. I. Webster, J. F. Wiggins, **S. H. Leppla**, and E. M. Sternberg
Endocrine perturbation increases susceptibility of mice to anthrax lethal toxin
Infect. Immun. 73:4238-4244. 2005
143. Abi-Habib, R. J., J. O. Urieto, S. Liu, **S. H. Leppla**, N. S. Duesbery, and A. E. Frankel
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin
Mol. Cancer Ther. 4:1303-1310. 2005.
144. Karginov, V., E. M. Nestorovich, M. Moayeri, **S. H. Leppla**, and S. M. Bezrukov

Blocking anthrax lethal toxin at the protective antigen channel by using structure_inspired drug design
Proc. Natl. Acad. Sci USA, 102:15075-15080. 2005.

145. Firoved, A.M., G. F. Miller, M. Moayeri, R. Kakkar, Y. Shen, J. F. Wiggins, E. M. McNally, W.J. Tang, and S. H. Leppla
Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice
Am. J. Pathol. 167:1309-1320. 2005.

146. Koya, V., M. Moayeri, S. H. Leppla, and H. Daniell.
Plant based vaccine: mice immunized with chloroplast_derived anthrax protective antigen survive anthrax lethal toxin challenge
Infect. Immun. 73:8266-8274. 2005.

147. Shivachandra, S. B., M. Rao, L. Janosi, T. Sathaliyawala, G. R. Matyas, C. R. Alving, S. H. Leppla, and V. B. Rao
In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins
Virology, 2005, epub

148. Leppla, S. H.
Bacillus anthracis toxins
Chapter 18, p. 323-347, in The Comprehensive Sourcebook of Bacterial Protein Toxins, 3rd ed., M. Popoff and J. Alouf, eds., Academic Press. 2005.

149. Pomerantsev, A. P., R. Sitaraman, C. R. Galloway, V. Kivovich, and S. H. Leppla
Genome engineering in *Bacillus anthracis* using Cre recombinase
Infect. Immun. 74:682-693. 2006.

150. Peachman, K. K., M. Rao, C. R. Alving, R. Burge, S. H. Leppla, V. B. Rao, and G. R. Matyas
Correlation between lethal toxin neutralizing antibody titers and protection from intranasal challenge with *Bacillus anthracis* Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen
Infect. Immun. 74:794-797. 2006.

151. Abrami, L., S. Thurneer, S. H. Leppla, and F. G. van der Goot
Receptor palmitoylation and ubiquitination regulate anthrax intoxication
J. Cell Biol. epub 2006

152. Duverger, A., R. J. Jackson, F. W. van Ginkel, R. Fischer, T. Loughlin, A. Tafaro, S. H. Leppla, K. Fujihashi, H. Kiyono, J. R. McGhee, and P. N. Boyaka
Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens
J. Immunol. 176:1776-1783. 2006.

153. Gozes, Y., M. Moayeri, J. F. Wiggins, and S. H. Leppla
Anthrax lethal toxin mediates ketotifen-sensitive intradermal vascular leakage in certain inbred mice
Infect. Immun. 74:1266-1272. 2006.

154. Rønø, B., J. Rømer, S. Liu, T. H. Bugge, S. H. Leppla, and P. E. Kristjansen
Anti-tumor efficacy of a urokinase activation-dependent anthrax toxin.
Mol. Cancer Therap. 5:89-96. 2006.

155. Bugge, T. H., and S. H. Leppla
Anthrax target in macrophages unveiled
Nature Genet. 38:137-138. 2006.

156. Cui, X., Y. Li, X. Li, M. Haley, M. Moayeri, Y. Fitz, S. H. Leppla, and P. Q. Eichacker
Sublethal doses of *B. anthracis* lethal toxin inhibit inflammation with lipopolysaccharide and *Escherichia coli* challenge but have opposite effects on survival
J. Inf. Dis., 193:829-840. 2006.

ISSUED PATENTS

Leppla SH, Klimpel KR, Arora N, Singh Y. US Patent 5,591,631: Anthrax toxin fusion proteins, nucleic acid encoding same, Jan. 7, 1997.

Leppla SH, Klimpel KR, Arora N, Singh Y. US Patent 5,677,274: Anthrax toxin fusion proteins and related methods, Oct. 14, 1997.

Duesbery NS, Webb C, Leppla SH, Vande Woude G. US Patent 6,485,925: Anthrax lethal factor is a MAPK Kinase protease, Nov. 26, 2002.

Klimpel K, Goletz TJ, Arora N, Leppla SH, Berzofsky JA. US Patent 6,592,872. Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein, Jul. 15, 2003.

Anti-tumor efficacy of a urokinase activation dependent anthrax toxin*

Birgitte Rønø, John Rømer[#], Shihui Liu, Thomas H. Bugge, Stephen H. Leppla, and Paul E. G. Kristjansen

*The work was financially supported by the Danish Cancer Society, grant 00252 130 9240.

[#]Correspondence should be addressed to: John Rømer, Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Phone: +45 3545 5875, telefax: +45 3538 5450, E-mail: jromer@finsenlab.dk

Key words: uPA

uPAR

targeted therapy

anthrax toxin

anti-tumor

Abbreviations:

CMG2	Capillary morphogenesis gene 2
EF	Oedema factor
FP59	Fusion protein 59
LF	Lethal factor
LLC	Lewis lung carcinoma
PAI-1	Plasminogen activator inhibitor 1
PrAg	Protective antigen
TEM8	Tumor endothelial marker 8
uPA	Urokinase plasminogen activator
uPAR	Urokinase plasminogen activator receptor

Abstract

Previously, we have generated a potent pro-drug consisting of modified anthrax toxins that is activated by urokinase plasminogen activator (uPA). The cytotoxicity of the drug, PrAg-U2 + FP59, is dependent on the presence of receptor-associated uPA-activity. Local intradermal administration of PrAg-U2 + FP59 adjacent to the tumor nodules in mice with transplanted solid tumors had a potent anti-tumor effect. In succession of these experiments we have now investigated the systemic anti-tumor efficacy of PrAg-U2 + FP59.

C57Bl/6J mice bearing syngenic tumors derived from B16 melanoma, T241 fibrosarcoma, or Lewis Lung Carcinoma cells were treated with different mass ratios and doses of PrAg-U2 + FP59. Tumor volumes were recorded daily by caliper measurements. In some experiments dexamethasone was co-administered.

Our data show a significant anti-tumor effect of systemic administration of PrAg-U2 + FP59 in three syngenic tumor models. Optimal anti-tumor effect and low toxicity was obtained with a 25:1 mass ratio between the two components (PrAg-U2:FP59). The experiments show that PrAg-U2 + FP59 displays a clear dose-response relationship with regard to both anti-tumor efficacy and systemic toxicity. Dose-limiting toxicity appeared to be due to activation of the pro-drug by uPA-uPAR in the intestinal mucosa. Concurrent treatment with dexamethasone was found to prevent dose-limiting toxicity.

Taken together these data indicates that uPA-activated toxins may be promising candidates for targeted therapy of human cancers that over-express uPA and its receptor.

Introduction

Urokinase plasminogen activator (uPA) and its cellular receptor (uPAR) are part of a proteolytic system associated with degradation and remodelling of the extracellular matrix in cancer, a hallmark of malignant transformation (1-4). The serine protease uPA is secreted as an inactive pro-enzyme (pro-uPA) that after binding to uPAR can be converted to active cell-surface associated uPA. uPA in turn activates plasminogen to plasmin. The membrane assembly of the plasminogen activation (PA) system components is required to favour and confine plasminogen activation in proximity of the cell surface (5,6). uPA and uPAR are overexpressed in many types of human cancers, such as ductal breast carcinomas, colon adenocarcinomas, and squamous cell carcinomas in head and neck, lung, skin and oesophagus (2,7). The fact that both uPA and uPAR are overexpressed in cancer prompted the development of cytotoxic pro-drugs that are specifically activated by cell surface bound uPA (8,9).

Native anthrax toxin, secreted by the Gram-positive bacterium *Bacillus anthracis*, consists of three individually non-toxic protein components: protective antigen (PrAg), lethal factor (LF), and oedema factor (EF). PrAg binds to the specific cellular receptors, tumor endothelial marker 8 (TEM8) or capillary morphogenesis gene 2 (CMG2), and is subsequently cleaved by cell surface associated furin or furin-like proteases, leading to the dissociation of an amino-terminal fragment (10-14). The carboxy-terminal part of PrAg remains bound and self-associates to form a heptamer. The heptamer structure enables binding of LF and/or EF which result in insertion of the heptamer in endosomal membranes and subsequent translocation of LF and/or EF into the cytosol where they cause cytotoxicity (15-18). The obligatory requirement for proteolytic processing of PrAg at the cell surface provides a way to re-engineer the toxin for activation by other cell surface associated enzymes than furin. Based on the availability of phage display-derived synthetic uPA-cleavable sequences (19) we generated a uPA activation dependent form of the anthrax toxin protective antigen (PrAg-U2) in which the native furin cleavage site was replaced by a uPA cleavage site (8). To increase the cytotoxicity of LF, a fusion protein (fusion protein 59 [FP59]), consisting of residue 1-254 of LF and the catalytic domain of *Pseudomonas* exotoxin A, was constructed (20). The catalytic domain of *pseudomonas* exotoxin A consists of a ADP-ribosylation domain that catalyzes the covalent attachment of ADP to elongation factor 2 thereby blocking protein synthesis. Administration of PrAg-U2 together with FP59 constitutes a potent cytotoxic pro-drug requiring activation by uPA. Thus, cells displaying active cell surface bound uPA and expressing either TEM8 or CMG2 are killed by the drug due to a block of protein synthesis.

uPA and uPAR are either not expressed or only one of the components are expressed at low levels in normal tissues. The expression of both is readily induced during normal tissue remodelling processes, such as wound healing, mammary gland involution and trophoblast invasion (1,21,22). Despite the generally low expression of uPA and uPAR in normal tissues, toxicity in T cell areas of the spleen and lymph nodes, bone marrow, adrenal cortex, and osteoblasts following administration of PrAg-U2 + FP59 was observed in a previous study (9).

Both *in vitro* and *in vivo* it has been demonstrated previously that activation and cytotoxicity of co-administered PrAg-U2 + FP59 are dependent on the presence of active uPA on the cell surface. In culture, uPAR negative cells were found to be insensitive to the reengineered toxin and uPA negative cells only were sensitive when uPA was added to the medium. In addition, cultured cells could be rescued from PrAg-U2 + FP59-induced death by addition of blockers of the interaction between uPA and its receptor (8). Furthermore, PrAg-U2 showed cell-surface uPA-dependent toxin activation *in vivo*, as revealed by the complete lack of toxic effects in mice deficient in plasminogen, uPA, or uPAR at doses that were lethal to wild-type mice, indicating that the component of the plasminogen activator system are essential for activation of the toxin. In the same study, FP59 or FP59 in combination with a non-cleavable form of PrAg was tolerated well by mice even when administered in large doses (200 µg). Moreover, LLC tumors grown in plasminogen knockouts mice were unresponsive to treatment with the re-engineered toxin, confirming that an intact plasminogen activator system is required in order for the toxin to become activated. Furthermore, local intradermal injections of PrAg-U2 + FP59 beneath transplanted solid tumors showed a significant anti-tumor effect in three different murine cancers (9).

In succession of these studies, we have now documented the anti-tumor effect of PrAg-U2 + FP59 after systemic administration and have defined the dose-relationship between the anti-tumor effects and the toxicity of the pro-drug. Moreover, we have found that co-administration of dexamethasone dramatically increases the therapeutic window of the uPA activated toxin.

Materials and Methods

Tumor transplantation and Treatment

Lewis lung carcinoma (LLC) cells and B16 melanoma cells were grown in DMEM with 10% FBS. T241 fibrosarcoma cells were grown in DMEM with 1% glutamax/1% nonessential amino acid mix/10% FBS. The cells were maintained at 37°C in a humidified atmosphere of 5% CO₂. The cells (10⁶ cells/mouse) were injected subcutaneously in the right flank of C57Bl/6J mice. When the

tumors reached a volume of approximately 50 mm³, the mice were allocated in treatment arms of 7-13 mice with equal median tumor sizes, and the treatment was started (day 0). The mice were given intraperitoneal (i. p.) injections of PBS or PrAg-U2 + FP59 in PBS. The construction and purification of both PrAg-U2 and FP59 has previously been described (8,20). The mice were treated with three day intervals, starting at day 0. In one experiment, concurrent daily treatment with 5 mg/kg dexamethasone (Dexamethasone VETRANAL, Sigma-Aldrich, Copenhagen, Denmark) was carried out. The experiments were terminated at day 9 with the exception of experiment 4.

Animals

Institutional guidelines for animal welfare and experimental conduct were followed in all experiments. All mice (5-8 weeks old males) were obtained from Taconic M & B (Ry, Denmark). The mice were conditioned to the new environment for one week before starting the experiment. The mice were shaved before tumor cell implantation to facilitate size measurements of the tumors. All mice were ear-tagged to ensure identification of each individual mouse. This was done while the mice were anaesthetized by subcutaneous injections of ketamine (10 mg/kg) and xylazine (1 mg/kg) in isotonic 0.9 % NaCl solution. The mice were euthanized by cervical dislocation at the end of each experiment.

Tumor growth analysis

The sizes of the tumors were determined by daily caliper measurements of two orthogonal diameters in mm during the growth phase. The sizes were calculated by the following empirical formula (23):

$$\text{Tumor size} = d_1 \times d_2^{3/2} \times \pi/6 \times K$$

d1 and d2 are orthogonal diameters in mm (adjusted for skin thickness by subtracting 0.5 mm from the measurement)
K is an empirical constant = 0.67

Growth inhibitory effects were evaluated by comparison of tumor sizes (by two a tailed student's t-test) and by Kaplan-Meier log rank analysis. A value of p<0.05 was considered statistically significant.

Evaluation of toxicity

For each treatment dose the number of dead mice was recorded and the fractional occurrence of toxic death was expressed by a lethality index, calculated by the following formula:

$$\text{Lethality index} = \sum(10-dtx)/n \times 10$$

10 is the number of days of the experiment

dtx is the day of event (death of a mouse)

n is the number of mice in the treatment arm

The lethality index is the fraction of measurements lost due to toxicity relative to the total number of measurements, and therefore includes information not only on the number of mice dead in each treatment groups, but also on when the mice had died during the experiment. Further, the weight of the mice was recorded on a daily basis.

Histological analysis

For histological analysis intestines, lung, heart, liver, kidney, and spleen were dissected from B16 melanoma-bearing mice treated with 1.96 mg/kg PrAg-U2 + 0.052 mg/kg FP59 or PBS i. p. three times at three day intervals. The tissues were fixed overnight in 4% paraformaldehyde in PBS and embedded in paraffin. Five μm sections were deparaffinated, rehydrated, and stained with hematoxylin/eosin.

Cellular cytotoxicity assay

40,000 cells were cultured overnight in growth medium in 96-well plates. The cells were treated with PrAg-U2 (0-3000 ng/ml) combined with FP59 (50 ng/ml) for 24 hours. Cell viability was assayed by adding 40 μl of 5 mg/ml 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma-Aldrich, Copenhagen, Denmark) at 48 hours. The cells were incubated with MTT for one hour; the medium was removed, and the purple pigment produced by the cells was dissolved in 200 μl DMSO. Absorbance was measured at A_{570} . Cell viability (% of control) was plotted versus \log_{10} PrAg-U2 concentration.

Results

Significant anti-tumor effect of PrAg-U2 + FP59 administered systemically

We first assayed the anti-tumor effect of the uPA-activated toxin after intraperitoneal administration to Lewis Lung Carcinoma (LLC) transplanted mice. Mice bearing solid subcutaneous tumors of

approximately 50 mm³ volumes were allocated to treatment arms with different doses of PrAg-U2 + FP59 three times with three days intervals (day 0, 3 and 6). These mice were treated with different absolute doses, but all with a mass ratio of PrAg-U2 to FP59 of 3:1, in accordance with the ratio previously applied as local, intradermal/peritumoral injections (9). The lowest dose (0.2 mg/kg PrAg-U2 + 0.068 mg/kg) resulted in significant anti-tumor effect ($P < 0.05$), whereas the higher doses were lethal (Table I, experiment 1).

Comparison of different ratios of PrAg-U2:FP59

Anthrax receptors are ubiquitously expressed in virtually all types of mammalian cells, which implies that a relatively large amount of PrAg-U2 protein is necessary in order to saturate these binding sites. The efficiency of this toxin system may therefore be dependent on the ratio between the two components PrAg-U2 and FP59. To investigate this and approximate the optimal ratio between the two components, we compared the anti-tumor effect of three different doses of the toxin with PrAg-U2:FP59 ratios of 3:1, 10:1, and 25:1 by treating LLC-bearing mice with 0.2 mg/kg PrAg-U2 + 0.068 mg/kg FP59, 0.68 mg/kg PrAg-U2 + 0.068 mg/kg FP59, 1.70 mg/kg PrAg-U2 + 0.068 mg/kg FP59. The most pronounced anti-tumor effect was obtained with the 25:1 ratio between the two components (Figure 1 and Table I, experiment 2).

Using 25:1 to 50:1 ratios we next tested the effect of systemically applied toxin in mice bearing T241 fibrosarcomas or B16 melanomas. In the experiment with T241-bearing mice, three different doses of PrAg-U2 + FP59 were applied, two doses with a ratio of 25:1 of PrAg-U2 to FP59 (0.85 mg/kg PrAg-U2 + 0.034 mg/kg FP59 and 1.70 mg/kg PrAg-U2 + 0.068 mg/kg), and one dose of PrAg-U2 + FP59 with a ratio of PrAg-U2 to FP59 of 50:1 (2.00 mg/kg + 0.040 mg/kg). The highest dose with a mass ratio 25:1 and the dose with a ratio of 50:1 both resulted in significant tumor growth inhibition (Figure 2 and Table I, experiment 3). In the experiment with B16-bearing mice, three ratios of PrAg-U2 + FP59 were applied. FP59 was held at a constant dose (0.052 mg/kg) and the doses of PrAg-U2 were increased to give ratios of 25:1, 37.5:1 and 50:1. All these doses resulted in significant tumor growth inhibition of the B16 melanomas (Table I, experiment 4).

To investigate if prolonged treatment of the mice could further inhibit the tumor growth, we decided to extend the treatment period. LLC-bearing mice were treated with 1.00 mg/kg PrAg-U2 + 0.04 mg/kg FP59 day 0, 3, 6, 12, and 15. The treatment resulted in a significant anti-tumor effect: however, the extended treatment did not suppress tumor growth completely, indicating that not all uPAR positive tumor cells were killed by the treatment (Figure 3 and Table I, experiment 5)

Taken together these results demonstrate that PrAg-U2 + FP59 is active when administered systemically and that the pro-drug induces a significant growth delay in LLC, T241 and B16 transplanted tumors.

Dose-limiting toxicity after systemic treatment

In the experiments described above we observed a dose-limiting toxicity with the highest doses. As a measure of this toxicity we calculated a lethality index, which reflects not only how many of the mice that had died but also how early they had died (see materials and methods). To investigate if increasing the dose of either of the two components led to an increase in lethality in B16-bearing mice, we first kept the dose of FP59 at a constant level of 0.052 mg/kg, while the dose of PrAg-U2 was varied from 1.30 mg/kg, 1.96 mg/kg, or 2.61 mg/kg (Table I, experiment 4). The doses resulted in lethality indexes of 13%, 22%, and 36%, respectively, demonstrating that increasing the dose of PrAg-U2, when FP59 is kept at a constant level, results in an increase in lethality. Analogous to what is observed by increasing PrAg-U2 the lethality was increased from 11% to 50% in B16-bearing mice, when the dose of FP59 was increased from 0.048 mg/kg to 0.144 mg/kg and PrAg-U2 was held constant at 1.20 mg/kg (Table I, experiment 6).

All together seven different ratios of PrAg-U2 to FP59 were tested in the experiments, ranging from 3:1 to 50:1. To analyze the relationship between doses, ratios of the two components, and lethality, we plotted PrAg-U2 doses against the doses of FP59 for each ratio (Figure 4). For all the ratios tested, this plot shows that an increase in dose results in an increase of the lethality index.

Gross inspection of mice treated with the highest doses of PrAg-U2 + FP59 revealed ulcerations of the anal region and oedema of the small intestines (Figure 5B). No other gross pathology was noted in any mice as a result of the treatment. Histological investigation of intestines of mice treated with either vehicle or 1.96 mg/kg PrAg-U2 + 0.052 mg/kg FP59 revealed that the intestines of the toxin-treated mice were clearly affected by the treatment. The villi in the small intestine were severely inflamed, the tips of the villi were necrotic, and occasionally necrotic tissue was shed into the intestinal lumen (Figure 5D). The villi of the vehicle-treated animals appeared normal. No histological signs of toxicity were observed in the liver, lung, kidneys, heart, and spleen of the toxin-treated B16 melanoma-bearing mice (data not shown).

Dose-limiting toxicity is efficiently inhibited by dexamethasone

To investigate if supplying the mice with an anti-inflammatory drug could attenuate the dose-limiting toxicity, daily treatment with the glucocorticoid dexamethasone was initiated. B16-bearing mice were treated with 2.40 mg/kg PrAg-U2 + 0.048 mg/kg FP59, resulting in a lethality index of 20%. Concurrent treatment with dexamethasone reduced the lethality index to 1% (Figure 6 and Table I, experiment 7). In the same experiment we recorded the weight of the mice on a daily basis. Mice treated with 2.40 mg/kg PrAg-U2 + 0.048 mg/kg had a significant weight loss compared to PBS treated mice ($P < 0.05$). Interestingly, when the mice received dexamethasone in addition to PrAg-U2 + FP59 no weight loss was observed (Figure 7). Since dexamethasone has previously been reported to have growth inhibitory effects in B16 melanoma tumors (24), we specifically addressed this potential bias. Daily dexamethasone treatment of 5 mg/kg for 9 days did not induce significant growth delay of B16 melanomas.

Direct killing of tumor cells by PrAg-U2 + FP59

In order to clarify whether the anti-tumor effect of PrAg-U2 + FP59 observed *in vivo* is caused by direct killing of the tumor cells or by affecting the stroma, we analysed the cytotoxic effect of the toxin *in vitro* by a colorimetric cytotoxicity assay. All three murine cell lines were sensitive to PrAg-U2 + FP59 treatment (data not shown) in a dose-dependent manner, demonstrating that the cells express the component required for activation and intoxication of the cells. Furthermore, the results indicate that the *in vivo* anti-tumor effect is mediated at least in part by a direct effect on the tumor cells.

Discussion

The well-documented over-expression of uPA and uPAR in several types of cancer makes the plasminogen activation-system an attractive candidate for targeted therapy. In many experimental *in vivo* studies, the aim has been to block the plasminogen activation -system either with inhibitors of the active site of uPA (25-27), or with inhibitors of the uPA/uPAR interaction (for review see (7)). In the present approach we have utilized a two-component pro-drug system, PrAg-U2 + FP59, which consists of modified anthrax toxins that specifically kill cells dependent on the presence of cell-surface associated uPA-activity, resulting in a direct cytotoxic effect both *in vitro* and *in vivo* (8,9).

In our previous *in vivo* studies, local administration of the pro-drug resulted in a substantial anti-tumor effect and in some cases tumor eradication. PrAg-U2 + FP59 was injected intradermally in the area surrounding the tumor nodules in order to obtain high local concentrations of drug in and

around the tumors (9). Although local administration of PrAg-U2 + FP59 in clinical settings may be feasible and even desirable in special types of malignancies such as head and neck cancer or brain cancer, most cancer-treatment is systemic. We have therefore investigated the anti-tumor activity of PrAg-U2 + FP59 after systemic administration. Importantly, we find that the modified toxins have significant anti-tumor effects after intraperitoneal administration. The optimal ratio between PrAg-U2 and FP59 for systemic use is 25:1 instead of the 3:1 ratio used for local administration. The reason for the need of a larger excess of PrAg-U2 to FP59 for systemic administration is probably the existence of a “sink-effect” due to the ubiquitous expression of PrAg receptors in the normal tissues, particularly CMG2 and to some extent TEM8 (10,28). The anti-tumor effect of systemically administered drug was clearly dose-dependent. However, high doses of PrAg-U2 + FP59 also elicited toxicity. By dose-optimization, we could approximate the optimal treatment dose that shows a significant growth inhibitory effect and at the same time low toxicity. However, a definitive determination of the therapeutic window of the pro-drug is complicated by the two-component nature of the drug, and thus could not be defined by an absolute or single value since it depends on the dose of each of the two components. If a low dose of FP59 is administered a high dose of PrAg-U2 can be administered without toxicity and vice versa.

PrAg-U2 + FP59 targets cells that harbour receptor-bound uPA on their surface. In some types of cancer, uPA and uPAR are often expressed by the stromal cells and only in a subpopulation of the cancer cells, which means that the anti-tumor effect of PrAg-U2 + FP59 in such cases may be obtained either by direct killing of cancer cells, or indirectly by destruction of the cancer-associated stroma. In colon and breast cancer, uPAR is predominantly expressed by macrophages, whereas uPA is produced and secreted mainly from myofibroblasts (29-33). However, uPAR is also expressed by budding cancer cells in colon cancer (34) and may also be expressed at a certain level in some breast cancer cells (30,35). This expression pattern is clearly distinct from that observed in squamous cell carcinomas, in which the predominant expression of uPA and uPAR is seen in the cancer cells as typified by squamous cell cancer of the skin (36) and esophagus (37). Lung, head and neck, cervical and esophageal squamous cell carcinomas may thus be good candidates for PrAg-U2 + FP59 based therapy aiming at targeting the cancer cells directly.

The systemic toxicity of uPA activated toxin may be related to an inflammatory response elicited by PrAg-U2 + FP59. We therefore anticipated that steroid treatment with dexamethasone would alleviate toxicity. In addition to the anti-inflammatory effect, dexamethasone has been reported to decrease the level of uPAR expression (38). Co-administration of dexamethasone with a high dose

of PrAg-U2 + FP59 completely eliminated toxicity compared with the group that received PrAg-U2 + FP59 alone. Whether dexamethasone abrogates a general systemic inflammatory condition or a local tissue specific damage in the PrAg-U2 + FP59 treated mice needs to be investigated in more detail.

We have observed both gross and histological signs of intestinal affection in PrAg-U2 + FP59 treated mice that were clearly suffering from malaise. The finding of strong inflammation and necrosis in the tip of the intestinal villi indicate that this part of the villi is especially vulnerable to the toxin. The reason for this may be that both uPA and uPAR are expressed in the villi in the normal intestine. uPAR is expressed in the epithelial mucosa cells lining the villi and uPA is expressed in fibroblast-like cells located just beneath the epithelium, and may hence be found at the distal epithelium (39-41). In addition, CMG2 and TEM8 is expressed in the small intestine (10,42,43). The co-localised expression of the components required for activation of the pro-drug may thus explain the specific damage to the epithelial cells at the tip of the villi. In support of this hypothesis, our previous studies showed that PAI-1-deficient mice presented oedema and hemorrhagia of the small intestine even at very low PrAg-U2 + FP59 doses (9).

The mechanism of *in vivo* anti-tumor effect of PrAg-U2 + FP59 is still not clearly understood and need further analysis. Evidence from ours previous studies and studies by others (9,44) points both at a direct cytotoxic effect of PrAg-U2 + FP59 towards tumor cells and also at an anti-angiogenic effect. We observed pronounced tumor vascular damage with angiectasis, vascular stasis, and hemorrhagia in PrAg-U2 + FP59 treated Lewis Lung Carcinomas (9). However, the endothelial damage might be secondary to tumor cell cytotoxicity since the anti-tumor effect of PrAg-U2 + FP59 in Lewis Lung Carcinoma transplanted uPAR^{-/-} mice was equal to the effect seen in wild type mice (9). Histological investigations of tumor tissue from PrAg-U2 + FP59 treated Lewis Lung Carcinoma bearing mice, previously performed, showed cytoplasmatic shrinkage, nuclear condensation, and cessation of BrdU incorporation into the tumor cells. In addition, TUNEL staining revealed no increase in tumor cell apoptosis, suggesting that the tumor cells were undergoing necrotic cell death and not apoptosis. Furthermore, we have now demonstrated that PrAg-U2 + FP59 is capable of killing Lewis Lung Carcinoma, B16 melanoma and T241 fibrosarcoma cells *in vitro* by cytotoxicity experiments. It has previously been shown that Lewis Lung Carcinomas express both uPA (45) and uPAR (46). Taken together, these data strongly suggest that the anti-tumor effect is mediated, at least in part, by direct killing of the tumor cells.

In conclusion, we here provide evidence of potent anti-tumor effect after systemic administration of an uPA-activated toxin, and furthermore the possibility to block the dose-limiting toxicity by co-administration of dexamethasone. These findings warrant further development of uPA-activated toxins in the clinic for specific targeting of cancers with over-expression of uPA and uPAR.

Reference List

1. Dano K, Romer J, Nielsen BS et al. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. *APMIS* 1999;107:120-127.
2. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. *Cell Mol Life Sci* 2000;57:25-40.
3. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. *Int J Cancer* 1997;72:1-22.
4. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. *Cancer Metastasis Rev* 2003;22:205-222.
5. Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. *Biol Chem* 2004;385:103-136.
6. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. *Curr Pharm Des* 2003;9:1499-1528.
7. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. *Curr Pharm Des* 2004;10:2359-2376.
8. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. *J Biol Chem* 2001;276:17976-17984.
9. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. *Proc Natl Acad Sci U S A* 2003;100:657-662.
10. Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. *Proc Natl Acad Sci U S A* 2003;100:5170-5174.
11. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. *Science* 2000;289:1197-1202.
12. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. *Nature* 2001;414:225-229.
13. Bell SE, Mavila A, Salazar R et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. *J Cell Sci* 2001;114:2755-2773.
14. Gordon VM, Klimpel KR, Arora N, Henderson MA, Leppla SH. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. *Infect Immun* 1995;63:82-87.

15. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. *J Cell Biol* 2003;160:321-328.
16. Singh Y, Klimpel KR, Goel S, Swain PK, Leppla SH. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. *Infect Immun* 1999;67:1853-1859.
17. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. *J Biol Chem* 1994;269:20607-20612.
18. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. *Proc Natl Acad Sci U S A* 2002;99:7045-7048.
19. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. *J Biol Chem* 1997;272:20456-20462.
20. Arora N, Klimpel KR, Singh Y, Leppla SH. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of *Pseudomonas* exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. *J Biol Chem* 1992;267:15542-15548.
21. Romer J, Bugge TH, Pyke C et al. Impaired wound healing in mice with a disrupted plasminogen gene. *Nat Med* 1996;2:287-292.
22. Lund LR, Bjorn SF, Sternlicht MD et al. Lactational competence and involution of the mouse mammary gland require plasminogen. *Development* 2000;127:4481-4492.
23. Spang-Thomsen M, Nielsen A, Visfeldt J. Growth curves of three human malignant tumors transplanted to nude mice. *Exp Cell Biol* 1980;48:138-154.
24. Bhakoo HS, Paolini NS, Milholland RJ, Lopez RE, Rosen F. Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma. *Cancer Res* 1981;41:1695-1701.
25. Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. *Cancer Res* 1997;57:559-563.
26. Alonso DF, Tejera AM, Farias EF, Bal de Kier JE, Gomez DE. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. *Anticancer Res* 1998;18:4499-4504.
27. Zeslawska E, Jacob U, Schweinitz A, Coombs G, Bode W, Madison E. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. *J Mol Biol* 2003;328:109-118.
28. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. *Cancer Res* 2001;61:6649-6655.

29. Pyke C, Kristensen P, Ralfkiaer E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. *Am J Pathol* 1991;138:1059-1067.
30. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. *Histopathology* 1994;24:131-138.
31. Pyke C, Graem N, Ralfkiaer E et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. *Cancer Res* 1993;53:1911-1915.
32. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. *Am J Pathol* 1991;138:111-117.
33. Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. *Lab Invest* 1996;74:168-177.
34. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. *Cancer Res* 1995;55:4132-4139.
35. Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Muller M, Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. *Am J Pathol* 1997;150:1231-1244.
36. Romer J, Pyke C, Lund LR, Ralfkiaer E, Dano K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. *J Invest Dermatol* 2001;116:353-358.
37. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. *Am J Pathol* 2000;156:567-575.
38. Yoshida E, Tsuchiya K, Sugiki M, Sumi H, Mihara H, Maruyama M. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. *Inflammation* 1996;20:319-326.
39. Kristensen P, Eriksen J, Blasi F, Dano K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. *J Cell Biol* 1991;115:1763-1771.
40. Larsson LI, Skriver L, Nielsen LS, Grondahl-Hansen J, Kristensen P, Dano K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. *J Cell Biol* 1984;98:894-903.
41. Gibson PR, Birchall I, Rosella O, Albert V, Finch CF, Barkla DH, Young GP. Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover. *Gut* 1998;43:656-663.

42. Hanks S, Adams S, Douglas J et al. Mutations in the Gene Encoding Capillary Morphogenesis Protein 2 Cause Juvenile Hyaline Fibromatosis and Infantile Systemic Hyalinosis. *Am J Hum Genet* 2003;73.
43. Bonuccelli G, Sotgia F, Frank PG et al. Anthrax Toxin Receptor (ATR/TEM8) is Highly Expressed in Epithelial Cells Lining the Toxin's Three Sites of Entry (Lung, Skin, and Intestine). *Am J Physiol Cell Physiol* 2005.
44. Duesbery NS, Resau J, Webb CP et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. *Proc Natl Acad Sci U S A* 2001;98:4089-4094.
45. Skriver L, Larsson LI, Kielberg V et al. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. *J Cell Biol* 1984;2:752-7.
46. Solberg H, Lober D, Eriksen J et al. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. *Eur J Biochem* 1992;205:451-8.

Table I. Anti-tumor effect and toxicity of PrAg-U2 + FP59.

Experiment number (tumor type)	PrAg-U2 (mg/kg)	FP59 (mg/kg)	Ratio	Dexamethasone (5 mg/kg)	Lethality index [§]	Number of Mice	t-test (p-value)	Kaplan Meier (p-value)	Number of dead mice	Day of death
1 (LLC)	0.20	0.068	3:1	-	8%	10	0.0195	0.0117	2	5 and 7
	0.60	0.200	3:1	-	79%	10	-	-	10	1, 1, 1, 2, 2, 2, 3, 3, 3, and 3
	1.20	0.400	3:1	-	80%	10	-	-	10	1, 1, 1, 2, 2, 2, 2, 3, 3, and 3
	3.60	1.200	3:1	-	82%	10	-	-	10	1, 1, 1, 1, 1, 2, 2, 3, 3, and 3
2 (LLC) See Figure 1	0.20	0.068	3:1	-	0%	12	0.0004	NS	0	-
	0.68	0.068	10:1	-	3%	11	0.0005	0.0102	1	7
	1.70	0.068	25:1	-	20%	12	0.0001	0.0035	4	2, 4, 4, and 6
3 (T241) See Figure 2	0.85	0.034	25:1	-	0%	12	0.0360	NS	0	-
	2.00	0.040	50:1	-	6%	13	0.0022	0.0002	2	5 and 7
	1.70	0.068	25:1	-	23%	12	0.0060	0.0005	6	4, 4, 5, 6, 7, and 7
4 (B16)	1.30	0.052	25:1	-	13%	10	0.0002	0.0208	2	2 and 5
	1.96	0.052	37.5:1	-	22%	10	0.0246	0.0001	4	3, 5, 5, and 5
	2.61	0.052	50:1	-	36%	10	0.0043	0.0001	8	4, 5, 5, 5, 5, 5, 6, and 9
5* (LLC) See Figure 3	1.00	0.040	25:1	-	-	10	0.007	0.003	3	8, 11, and 14
6 (B16)	1.20	0.048	25:1	-	11%	8	NS	NS	4	5, 5, 8, and 9
	1.20	0.096	12.5:1	-	11%	8	0.0303	NS	3	6, 7, and 8
	1.20	0.144	8.3:1	-	50%	8	-	-	8	4, 4, 5, 5, 5, 5, 5, and 7
7 (B16) See Figure 6	-	-	-	+	0%	7	NS	NS	0	-
	2.40	0.048	50:1	-	20%	8	0.0255	0.0083	5	6, 6, 6, 7, and 9
	2.40	0.048	50:1	+	1%	9	0.0074	0.0079	1	9

[§]As defined in Materials and Methods.

*The mice were treated at day 0, 3, 6, 9, 12, and 15 as opposed to day 0, 3, and 6.

NS: not significant

Figure legends

Figure 1

The anti-tumor effect is dependent on the PrAg-U2:FP59 ratio. Upper panel: LLC bearing mice were treated with PBS (—●—), 0.2 mg/kg PrAg-U2 + 0.068 mg/kg FP59 (—○—), 0.68 mg/kg PrAg-U2 + 0.068 mg/kg FP59 (—▼—), or 1.7 mg/kg PrAg-U2 + 0.068 mg/kg (—▽—), giving ratios of PrAg-U2:FP59 of 3:1, 10:1, and 25:1, respectively. The most pronounced anti-tumor effect was observed with the ratio of 25:1, indicating that the effect is dependent on the ratio of the two components. The sizes of the tumors are expressed as mean tumor size in $\text{mm}^3 \pm \text{SEM}$. Lower panel: The number of remaining mice in each treatment group is showed in the lower panel of the figure. The symbols correspond to the symbols used in the upper panel of the figure.

Figure 2

Significant anti-tumor effect of PrAg-U2 + FP59 in T241 fibrosarcoma bearing mice. Upper panel: The mice were treated with PBS (—●—), 0.85 mg/kg PrAg-U2 + 0.034 mg/kg FP59 (—○—), 2.00 mg/kg + 0.040 mg/kg PrAg-U2 (—▼—), or 1.70 mg/kg PrAg-U2 + 0.068 mg/kg (—▽—) i. p. day 0, 3, and 6. The two highest doses of PrAg-U2 + FP59 resulted in significant anti-tumor effect, demonstrating the sensitivity of T241 fibrosarcoma towards PrAg-U2 + FP59 treatment. The sizes of the tumors are expressed as mean tumor size in $\text{mm}^3 \pm \text{SEM}$. Lower panel: The number of remaining mice in each treatment group is showed in the lower panel of the figure. The symbols correspond to the symbols used in the upper panel of the figure.

Figure 3

Prolonged treatment. Upper Panel: LLC-bearing mice were treated with PBS (—●—), 1.00 mg/kg PrAg-U2 + 0.04 mg/kg FP59 (—○—) i. p. at day 0, 3, 6, 9, 12, and 15. The dose resulted in significant anti-tumor effect, but the extended treatment could not completely inhibit the growth of the tumors. Lower panel: The number of remaining mice in the treatment group is showed in the lower panel of the figure. The symbol corresponds to the symbol used in the upper panel of the figure.

Figure 4

Lethality index is increased when the dose is increased. The lines represent different ratios of PrAg-U2:FP59 tested in C57Bl/6J mice by the three times three days interval dosage schedule, and the numbers refer to the lethality index induced by the dose. The figure illustrates that when keeping the ratio between the two components constant the toxicity increases when the dose of PrAg-U2 + FP59 is increased. Note: the two highest doses tested are not included in the figure.

Figure 5

PrAg-U2 + FP59-induced toxicity. Intestines of untreated C57Bl/6J mice (A) or mice treated with PrAg-U2 + FP59 (B). Small intestinal oedema was observed in mice treated with 2.4 mg/kg PrAg-U2 + 0.24 mg/kg FP59. Hematoxylin/eosin stained sections of small intestines from mice treated with PBS (C) or 1.96 mg/kg PrAg-U2 + 0.052 mg/kg FP59 (D). Note that the tip of the villi of the small intestine of the PrAg-U2 + FP59 treated mice are necrotic (arrows).

Figure 6

Protective effect of dexamethasone. Upper panel: B16 melanoma bearing mice were treated with PBS (—●—), dexamethasone (—○—), 2.40 mg/kg PrAg-U2 + 0.048 mg/kg FP59 (—▼—), 2.40 mg/kg PrAg-U2 + 0.048 mg/kg FP59 together with dexamethasone (—▽—) i. p. day 0, 3, and 6. Daily dexamethasone treatment itself did not result in significant growth delay in B16 melanoma tumors. The PrAg-U2 + FP59 treatment resulted in a significant anti-tumor effect. Co-administration of dexamethasone reduced the lethality index of 2.40 mg/kg PrAg-U2 + 0.048 mg/kg FP59 from 20% to 1%, suggesting a protective function of dexamethasone. The sizes of the tumors are expressed as mean tumor size in $\text{mm}^3 \pm \text{SEM}$. Lower panel:

Figure 7

Co-administration of dexamethasone attenuates PrAg-U2 + FP59 induced weight loss. The weight of mice treated with PBS (—●—), 2.40 mg/kg PrAg-U2 + 0.048 mg/kg FP59 (—○—), 2.40 mg/kg PrAg-U2 + 0.048 mg/kg FP59 together with dexamethasone (—▼—) i. p. day 0, 3, and 6 was recorded daily. The mice treated with PrAg-U2 + FP59 alone had a significant weight loss compared to PBS treated mice, while in mice receiving PrAg-U2 + FP59 in combination with dexamethasone no weight loss was observed.

Figures

Figure 1





Figure 2




Figure 3




Figure 4




Figure 5




Figure 6







Figure 7



Supplementary Table 1. Properties and maximum tolerated doses of the PrAg proteins when injected intraperitoneally at days 0, 3, and 6

PrAg proteins or their combination	Proteolytic cleavage	Group L mutation Subsite II	Group R mutation		MTD3 (g) FP59=3 g
			Subsite I	Subsite III	
PrAg	Furin				0.25
PrAg-R200A	Furin	R200A			ND
PrAg-I210A	Furin			I210A	ND
PrAg-L1	MMP				4
PrAg-L1-R178A	MMP		R178A		ND
PrAg-L1-I210A	MMP			I210A	50
PrAg-L1-K214A	MMP			K214A	50
PrAg-U2	uPA				10
PrAg-U2-K197A	uPA	K197A			ND
PrAg-U2-R200A	uPA	R200A			100
PrAg-U2-R200A	uPA	R200A			30
PrAg-L1-I210A	MMP			I210A	15
PrAg-U2-R200A	uPA	R200A			30
PrAg-L1-K214A	MMP			K214A	15

ND: not done. PrAg-L1: previously characterized MMP-activated PrAg protein with furin site RKKR changed to MMP cleavage sequence GPLGMLSQ. PrAg-U2: previously characterized uPA-activated PrAg protein with furin site RKKR changed to uPA cleavage sequence PGSGRSA.



Supplementary Figure 1. Toxicity of the engineered PrAg proteins. Representative microscopic appearance of the bone and bone marrow (femur) at day 7 after treatment of the mice with PBS (**a**) or PrAg-U2-R200A/PrAg-L1-I210A (**b-d**) (45/22.5 μ g, in the presence of 3 μ g FP59) at day 0, 3, and 6. The bone marrow necrosis was observed in toxin-treated mice (**b**, H&E, 64 \times) but not in the mock-treated mice (**a**, H&E, 64 \times). At higher magnification, the necrotic area shows cellular debris and necrotic bone trabeculae (**c**); fibroblastic and vascular proliferations are seen in the periphery of damaged area representing ongoing repair processes (**d**).